AGEN
USDAgenus Inc. Common Stock
Цена в режиме реального времени
График цен
Ключевые показатели
Рыночные показатели
Открытие
$3.840
Максимум
$3.980
Минимум
$3.700
Объем
0.33M
Фундаментальные показатели компании
Рыночная капитализация
126.8M
Отрасль
Биотехнология
Страна
United States
Статистические данные торговли
Средний объем
0.46M
Биржа
NCM
Валюта
USD
52-недельный диапазон
Связанные новости
HC Wainwright & Co. Reiterates Buy on Agenus, Maintains $23 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates Agenus with a Buy and maintains $23 price target.
France Grants Reimbursed Compassionate Access (AAC) for Agenus' BOT/BAL in Refractory MSS Metastatic Colorectal Cancer
Agenus Inc. (NASDAQ:AGEN), a leader in immuno‑oncology, today announced its investigational combination botensilimab plus balstilimab (BOT/BAL) is now available to eligible patients with refractory microsatellite‑stable
Agenus Inc. (AGEN) Virtual Stakeholder Briefing Call (Transcript)
Agenus Inc. (AGEN) Virtual Stakeholder Briefing Call (Transcript)
FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone
Federal budget cuts have put pressure on cancer research efforts in the United States, but private investment is helping to fill the gap, with...
HC Wainwright & Co. Reiterates Buy on Agenus, Maintains $23 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates Agenus with a Buy and maintains $23 price target.
Update: Agenus Aug 27 Stakeholder Webcast—Transformative IO Updates, BOT/BAL Data, BATTMAN Preview, Zydus Partnership Momentum, and MiNK Spotlight
Webcast details updated from the August 11th release Webcast on Wednesday, August 27, 2025 at 4:00 p.m. EST Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, today announced an update to its
Связанные акции
Оставаться в курсе
Установите ценовой сигнал, получите обновления анализа ИИ и новости рынка в режиме реального времени.